Thin
Mazdutide API (CAS NO: 2259884-03-0)
Oxyntomodulin dual agonist for obesity and MASH. Purity ≥99.0% by RP-HPLC, endotoxins <5 EU/mg.
Engineered for high-throughput generic solid-dosage, injectable, and intranasal formulation pipelines with validated stability under harsh continental climate freight conditions.
Oxyntomodulin dual agonist for obesity and MASH. Purity ≥99.0% by RP-HPLC, endotoxins <5 EU/mg.
Heptapeptide ACTH(4-10) analogue for ischemic stroke & cognitive therapy. Commercial bulk lots available.
Mitochondria-encoded peptide stimulating AMPK pathways for metabolic balance and longevity research.
Long-acting acylated amylin receptor agonist formulated synergistically with GLP-1 analogues for clinical programs.
Strategic analysis of therapeutic peptide API availability, raw material import dependency, and regulatory integration within the Russian Ministry of Health and EAEU framework.
The pharmaceutical landscape in the Russian Federation is navigating a profound transformation driven by the national "Pharma 2030" Strategy. Historically reliant on imported European active pharmaceutical ingredients (APIs), domestic Russian pharmaceutical conglomerates and contract manufacturing organizations (CMOs) are rapidly reconfiguring their supply networks. Under Russian Government Decree No. 719 and related localization mandates, state drug tenders prioritize manufacturers capable of proving localized synthesis or secure, uncompromised access to high-purity bulk substance inputs. However, while formulation capabilities (fill-and-finish, sterile ampoule lyophilization, auto-injector assembly) are highly mature in bio-clusters such as the Moscow Technopolis, Saint Petersburg Bio-pharmaceutical Cluster, and Novosibirsk Academic Park, domestic chemical synthesis of complex peptide sequences remains severely constrained.
Peptide APIs—characterized by multi-step solid-phase peptide synthesis (SPPS), complex chain cyclization, and delicate stereochemical purifications—represent one of the highest technical hurdles in fine chemical production. The local synthesis of long-chain metabolic agonists (e.g., Mazdutide, Cargrilintide) and neuroprotective peptides (e.g., Semax) requires vast quantities of specialized Fmoc-protected amino acids, coupling reagents (such as HATU, HBTU, and PyBOP), and industrial-scale preparative high-performance liquid chromatography (RP-HPLC) infrastructure. Due to current international logistics realities, direct partnerships with high-capacity API synthesis powerhouses in China have transitioned from an opportunistic purchasing channel into a fundamental pillar of national healthcare supply security.
The harmonization of national pharmacopoeias within the Eurasian Economic Union (incorporating Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan) has set elevated benchmarks for monograph compliance. The State Pharmacopoeia of the Russian Federation (XIV and emerging XV Editions) strictly enforces limits on residual organic solvents, trifluoroacetic acid (TFA) counter-ion content, bioburden, and bacterial endotoxins—particularly for parenteral and intranasal preparations.
Western sanctions and logistical friction have exacerbated lead times and introduced exorbitant third-party currency conversion fees for European products. In response, our dedicated Russia & CIS Supply Desk provides a friction-free bilateral commercial framework. By maintaining direct clearance channels, offering cross-border direct payment settlement in Chinese Yuan (RMB) and Russian Rubles (RUB) through non-sanctioned clearing banks, and maintaining temperature-controlled air freight connections between Hangzhou and Moscow (SVO/DME), we guarantee lead-time stability under 10 business days for commercial catalog APIs.
Overcoming racemization, deletion impurities, and aggregation in difficult-to-synthesize peptide chains using multi-ton hybrid synthesis and continuous purification.
For therapeutic peptides exceeding 30 amino acids (such as Mazdutide and Teduglutide), linear solid-phase synthesis yields often suffer from sequence aggregation and sterically hindered couplings. We utilize segment condensation approaches.
Purification of complex peptide crude isolates demands multi-column orthogonal selectivity. Our facility leverages dual-stage preparative dynamic axial compression (DAC) columns packed with spherical C18/C8 silica matrices.
Full batch release analytics meeting ICH Q2(R1) and Russian Pharmacopoeia requirements. Ensuring every lot shipped to EAEU territory maintains validated shelf-life stability.
Therapeutic peptide API procurement for the Russian generic formulation sector requires meticulous scrutiny of impurity profiles. Unlike small-molecule APIs, synthetic peptides exhibit complex impurity spectra comprising truncated peptides, deletion sequences, insertion products, and stereoisomeric variants (D-amino acid diastereomers). In compliance with the EAEU Guideline on Evaluation of Impurities in Peptide Drug Substances, our manufacturing process maintains individual unknown impurities strictly below 0.10% and total related impurities below 1.0%.
| Test Parameter | Standard Acceptance Criteria | Analytical Methodology | Relevance for Russian Formulation |
|---|---|---|---|
| Appearance | White or almost white amorphous, lyophilized powder | Visual inspection | Solubility and cake reconstitution uniformity |
| Identification (MS) | Monoisotopic / Average MW matches theoretical ±0.5 Da | LC-ESI-HRMS / MALDI-TOF | Pharmacopoeial molecular confirmation |
| Purity (RP-HPLC) | ≥ 98.0% to ≥ 99.5% (Product specific) | Orthogonal Dual RP-HPLC (C18, UV 214nm/220nm) | Dossier registration requirement (EAEU No. 78) |
| Related Substances | Largest Single Impurity ≤ 0.5%; Unknown Impurity ≤ 0.10% | Gradient Reverse Phase HPLC | Immunogenicity mitigation for injectables |
| Peptide Content (N-content) | ≥ 80.0% to ≥ 88.0% (Net base) | Elemental Analysis / Quantitative Amino Acid Analysis | Accurate finished formulation dosage calculation |
| Counter-Ion Content | Acetate: 4.0% - 12.0% (or specific TFA < 0.25%) | Ion Chromatography (IC) or RP-HPLC with Conductivity | Tissue tolerability and pH balance in liquid vials |
| Bacterial Endotoxins | < 5.0 EU/mg (or as per finished product limit) | LAL Kinetic Turbidimetric / Chromogenic | Pyrogen-free compliance for parenteral delivery |
| Residual Solvents | Acetonitrile < 410 ppm, DMF < 880 ppm, DCM < 600 ppm | Headspace Gas Chromatography (HS-GC-FID/MS) | ICH Q3C(R8) toxicity containment compliance |
Strategic deployment of specific peptide API classes addressing high-incidence pathologies within the Russian domestic healthcare system.
The Russian clinical pharmacology sector has historically pioneered regulatory acceptance of regulatory oligopeptides for neuroprotection. Peptides such as Semax (CAS 80714-61-0) and its companion Selank occupy prominent positions in the Russian State Pharmacopoeia and the Vital and Essential Drugs List (ZhNVLP). Synthesized as synthetic analogues of adrenocorticotropic hormone ACTH(4-10) and tuftsin, respectively, these molecules lack hormonal side-effects while modulating brain-derived neurotrophic factor (BDNF) and serotonergic neurotransmission.
Domestic manufacturers in Moscow and Saint Petersburg formulate Semax into intranasal drops for post-stroke rehabilitation, traumatic brain injury (TBI) recovery, and cognitive enhancement. With incidence rates of cerebrovascular events remaining a national healthcare focus in Russia, securing bulk, high-purity Semax API with validated optical rotation and minimal D-isomer impurities is vital for generic market stability.
The withdrawal of major multinational brand leaders from the Russian anti-diabetic and anti-obesity sector created an acute shortage of weekly GLP-1 receptor agonists. Russian pharmaceutical enterprises responded with rapid generic approvals of semaglutide. However, the global clinical frontier is shifting toward multi-receptor co-agonists.
Mazdutide (CAS 2259884-03-0), a dual GLP-1R and glucagon receptor (GCGR) agonist, delivers superior hepatic lipid clearance and energy expenditure compared to pure GLP-1 monotherapy—directly addressing non-alcoholic steatohepatitis (NASH/MASH) and morbid obesity. Concurrently, Cargrilintide (CAS 1415456-99-3) and non-peptide oral mimics like Orforglipron (CAS 2212020-52-3) represent the future of combination obesity therapy. By supplying technical-grade and GMP-compliant active substances of these novel molecules, we empower Russian R&D centers to conduct bioequivalence and pilot clinical trials years ahead of off-patent generic windows.
Russia is globally renowned for its extensive research into peptide bioregulators and thymus-derived immunomodulators. Thymalin (CAS 63958-90-7) and Thymosin Alpha 1 (CAS 62304-98-7) represent standard therapeutic interventions in secondary immunodeficiency states, chronic post-viral pulmonary fibrosis, and adjunct oncology protocols across Russian regional clinical hospitals. Sourcing synthetic Thymalin and high-purity Thymosin Alpha-1 with guaranteed freedom from animal-derived adventitious agents (BSE/TSE) allows local formulators to upgrade older bovine-extracted products into precise, synthetically pure, reproducible finished dosage forms.
Musculoskeletal disorders, sports rehabilitation, and gastrointestinal mucosal damage represent significant clinical demands in commercial clinical centers. BPC-157 (CAS 137525-51-0), a stable 15-amino acid fragment of body protection compound, alongside Thymosin β4 (TB-500, CAS 77591-33-4), is undergoing intensive preclinical and clinical evaluation in wound healing, corneal ulceration, and tendon repair formulations. In gastrointestinal specialty medicine, Teduglutide (CAS 287714-30-1), an acylated GLP-2 analogue, serves as an indispensable life-saving therapy for Short Bowel Syndrome (SBS), restoring intestinal villus architecture and parenteral nutrition independence.
Understanding volume-tiered valuation, analytical release costs, and direct currency clearance mechanisms for Russian procurement officers.
Pricing for therapeutic peptide active pharmaceutical ingredients differs significantly from standard small-molecule commodities. Due to the high stoichiometry of protected amino acids, raw solvent volumes, and specialized column packing media, peptide pricing operates on tiered industrial scale brackets: Gram-scale R&D Pilot lots (10g - 100g), Engineering Registration Batches (500g - 2kg), and Commercial Multi-Kilogram Supply Contracts (>5kg - 50kg+).
| Peptide API Name | CAS Number | Standard Therapeutic Class | Indicative Commercial Grade | Supply Scale & Lead Time |
|---|---|---|---|---|
| Mazdutide | 2259884-03-0 | Dual GLP-1 / Glucagon Agonist | HPLC ≥ 98.5%, Lyophilized Powder | 100g / 1kg / 5kg (4-6 weeks) |
| Semax | 80714-61-0 | ACTH(4-10) Neuroprotective Analogue | Ru State Ph. ≥ 99.0%, Acetate | Stock in Bulk / Kg Scale (Immediate) |
| MOTS-c | 1627580-64-6 | Mitochondrial Metabolic Regulator | HPLC ≥ 98.0%, Desalt / Acetate | 50g / 500g / 2kg (2-3 weeks) |
| Cargrilintide | 1415456-99-3 | Acylated Long-Acting Amylin Agonist | HPLC ≥ 98.5%, Ultra-pure | 100g / 1kg (4-5 weeks) |
| Teduglutide | 287714-30-1 | GLP-2 Analogue (Short Bowel Syndrome) | HPLC ≥ 99.0%, Sterile/Low Bioburden | 50g / 500g / 2kg (Commercial Campaign) |
| Vasopressin | 50-57-7 | Antidiuretic / Vasopressor Nonapeptide | EP / USP / Ru Ph. Grade ≥ 99.0% | Stock Available / Up to 10kg |
| Orforglipron | 2212020-52-3 | Non-Peptide Oral GLP-1 Receptor Agonist | Chemical Purity ≥ 99.0% | 500g / 5kg / 25kg (Custom Batch) |
| Thymosin β4 (TB-500) | 77591-33-4 | Tissue Regeneration / Actin-Sequestering | HPLC ≥ 98.5%, Acetate Salt | 100g / 1kg / 5kg (In Stock) |
| BPC-157 | 137525-51-0 | Pentadecapeptide Gastrointestinal Restorative | HPLC ≥ 99.0%, Acetate / Arginate | Multi-Kg Inventory (Immediate Dispatch) |
| Bremelanotide (PT-141) | 189691-06-3 | Melanocortin Receptor Agonist (MC3R/MC4R) | HPLC ≥ 98.5%, Cyclic Hexapeptide | 100g / 1kg (Stock) |
| Thymosin Alpha 1 | 62304-98-7 | Synthetic 28-AA Immunomodulator | EP / USP Grade ≥ 99.0% | 500g / 5kg (High Volume Scale) |
| Thymalin | 63958-90-7 | Synthetic Thymic Polypeptide Complex | Ru Ph. Specific, Bioactive Grade | 100g / 1kg / 10kg (Immediate Dispatch) |
Executing API procurement under prevailing economic restrictions requires modern financial and logistical conduits:
Manufactured under stringent process analytical technology (PAT) with complete batch traceability and analytical dossiers ready for import licensing.
Short bowel syndrome peptide API. Multi-gram to commercial kilogram lots with DMF Module 3 support.
High-purity cyclic nonapeptide for emergency hemodynamics, diabetes insipidus, and shock resuscitation.
Next-generation non-peptide oral agonist. High bioavailability, robust crystal form control for tablet formulation.
43-amino acid regenerative peptide promoting cell migration and tissue repair. High purity lyophilized bulk.
Pentadecapeptide accelerating tendon, ligament, and gut mucosal healing. Pure acetate and stable arginate salt options.
Lactam-bridge cyclic peptide active for sexual dysfunction therapies. Batch stability data and impurity profile available.
28-amino acid polypeptide stimulating T-cell differentiation. Commercial scale API with low endotoxin levels.
Pure synthetic thymic peptide formulation meeting Russian state healthcare specifications for immunomodulatory vials.
Expert answers addressing the practical regulatory, analytical, and supply chain realities of importing therapeutic peptide APIs into the Russian Federation and EAEU member states.
Connect directly with our senior peptide synthesis chemists and regional Russia & CIS supply specialists. Whether you require pilot quantities for analytical bioequivalence or multi-kilogram commercial contracts, we deliver uncompromised purity and regulatory confidence.